Clinical Trials Browser

Phase 2 × ganitumab × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01318642 2024-11-08

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

Phase 2 Terminated

10 enrolled 10 charts

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT04129151 2024-08-01

Palbociclib + Ganitumab In Ewing Sarcoma

Phase 2 Terminated

10 enrolled 15 charts

Recurrence, Sarcoma, Sarcoma, Ewing

NCT00891930 2024-07-17

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Phase 2 Completed

74 enrolled 15 charts

Gastrointestinal

Colorectal Neoplasms

NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Phase 2 Completed

12 enrolled 21 charts

EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT01024387 2018-03-08

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Phase 2 Completed

60 enrolled 7 charts

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT00813605 2016-10-27

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms